Intriguingly, an enzyme-linked immunosorbent assay (ELISA) detected a two-fold increase in Wnt5a in the femur when compared to the humerus and knockdown of WNT5a in a bone marrow stromal cell line (HS-5) significantly reduced LNCaP and PC-3 prostate cancer cell invasion in vitro [211]. This evidence concerns the gene WNT5A and prostate carcinoma.